Kymera Therapeutics to Report Third Quarter 2023 Financial Results on November 2
26 Octubre 2023 - 6:00AM
Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage
biopharmaceutical company advancing a new class of small molecule
medicines using targeted protein degradation, will report third
quarter 2023 financial results on November 2, 2023, and will host a
conference call at 8:00 a.m. ET that day.
To access the November 2 conference call via phone, please dial
+1 (833) 630-2127 (US) or +1 (412) 317-1846 (International) and ask
to join the Kymera Therapeutics call. A live webcast of the
Company’s conference call will be available under the “Events and
Presentations” section of the Investors page on the Company’s
website at www.kymeratx.com.
About Kymera Therapeutics
Kymera is a biopharmaceutical company pioneering the field of
targeted protein degradation, a transformative approach to address
disease targets and pathways inaccessible with conventional
therapeutics. Kymera’s Pegasus platform is a powerful drug
discovery engine, advancing novel small molecule programs designed
to harness the body’s innate protein recycling machinery to degrade
dysregulated, disease-causing proteins. With a focus on undrugged
nodes in validated pathways, Kymera is advancing a pipeline of
novel therapeutic candidates designed to address the most promising
targets and provide patients with more effective treatments.
Kymera’s initial programs target IRAK4, IRAKIMiD, and STAT3 within
the IL-1R/TLR or JAK/STAT pathways, and the MDM2 oncoprotein,
providing the opportunity to treat patients with a broad range of
immune-inflammatory diseases, hematologic malignancies, and solid
tumors.
Founded in 2016, Kymera is headquartered in Watertown, Mass.
Kymera has been named a “Fierce 15” company by Fierce Biotech and
has been recognized by both the Boston Globe and the Boston
Business Journal as one of Boston’s top workplaces. For more
information about our people, science, and pipeline, please visit
www.kymeratx.com or follow us on Twitter or LinkedIn.
Cautionary Note Regarding Forward-Looking
Statements This press release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, as amended, including,
without limitation, implied and express statements by Kymera
Therapeutics regarding its: strategy, business plans and objectives
for the IRAK4, IRAKIMiD, STAT3, and MDM2 degrader programs; plans
and timelines for the preclinical and clinical development of its
product candidates, including the therapeutic potential, clinical
benefits and safety thereof; expectations regarding timing, success
and data announcements of current ongoing preclinical and clinical
trials; the ability to initiate new clinical programs; and Kymera’s
financial condition and expected cash runway into the second half
of 2025. The words "may," “might,” "will," "could," "would,"
"should," "expect," "plan," "anticipate," "intend," "believe,"
“expect,” "estimate," “seek,” "predict," “future,” "project,"
"potential," "continue," "target" and similar words or expressions
are intended to identify forward-looking statements, although not
all forward-looking statements contain these identifying words. Any
forward-looking statements in this press release are based on
management's current expectations and beliefs and are subject to a
number of risks, uncertainties and important factors that may cause
actual events or results to differ materially from those expressed
or implied by any forward-looking statements contained in this
press release, including, without limitation, risks associated with
the timing and anticipated results of our current and future
preclinical studies and clinical trials, supply chain, strategy and
future operations; the delay of any current and future preclinical
studies or clinical trials or the development of Kymera
Therapeutics' drug candidates; the risk that the results of current
preclinical studies and clinical trials may not be predictive of
future results in connection with current or future preclinical and
clinical trials, including those for KT-474 (SAR444656), KT-333,
KT-413 and KT-253; Kymera Therapeutics' ability to successfully
demonstrate the safety and efficacy of its drug candidates; the
timing and outcome of the Kymera Therapeutics' planned interactions
with regulatory authorities; obtaining, maintaining and protecting
its intellectual property; the risks associated with pandemics or
epidemics; and Kymera Therapeutics' relationships with its existing
and future collaboration partners. These and other risks and
uncertainties are described in greater detail in the section
entitled "Risk Factors" in the Annual Report on Form 10-K for the
period ended December 31, 2022 and most recent Quarterly Report on
Form 10-Q, as well as discussions of potential risks,
uncertainties, and other important factors in Kymera Therapeutics'
subsequent filings with the Securities and Exchange Commission. In
addition, any forward-looking statements represent Kymera
Therapeutics' views only as of today and should not be relied upon
as representing its views as of any subsequent date. Kymera
Therapeutics explicitly disclaims any obligation to update any
forward-looking statements. No representations or warranties
(expressed or implied) are made about the accuracy of any such
forward-looking statements.
Investor
Contact: Justine Koenigsberg Vice
President, Investor
Relations investors@kymeratx.com 857-285-5300 |
Media
Contact: Todd Cooper Senior Vice
President, Corporate
Affairs media@kymeratx.com 857-285-5300 |
Kymera Therapeutics (NASDAQ:KYMR)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
Kymera Therapeutics (NASDAQ:KYMR)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024